{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:22:24Z","timestamp":1793607744464,"version":"4.5.0"},"reference-count":401,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013061","name":"Jilin Provincial Scientific and Technological Development","doi-asserted-by":"publisher","award":["20240404036ZP"],"award-info":[{"award-number":["20240404036ZP"]}],"id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The recent introduction of the term metabolic-dysfunction-associated steatotic liver disease (MASLD) has highlighted the critical role of metabolism in the disease\u2019s pathophysiology. This innovative nomenclature signifies a shift from the previous designation of non-alcoholic fatty liver disease (NAFLD), emphasizing the condition\u2019s progressive nature. Simultaneously, MASLD has become one of the most prevalent liver diseases worldwide, highlighting the urgent need for research to elucidate its etiology and develop effective treatment strategies. This review examines and delineates the revised definition of MASLD, exploring its epidemiology and the pathological changes occurring at various stages of the disease. Additionally, it identifies metabolically relevant targets within MASLD and provides a summary of the latest metabolically targeted drugs under development, including those in clinical and some preclinical stages. The review finishes with a look ahead to the future of targeted therapy for MASLD, with the goal of summarizing and providing fresh ideas and insights.<\/jats:p>","DOI":"10.3390\/ijms26094077","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:10:13Z","timestamp":1745561413000},"page":"4077","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeting Metabolism: Innovative Therapies for MASLD Unveiled"],"prefix":"10.3390","volume":"26","author":[{"given":"Weixin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[{"name":"School of Public Health, Jilin University, Changchun 130021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentong","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Yin","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun 130041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1966-4088","authenticated-orcid":false,"given":"Kan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s12072-024-10704-3","article-title":"Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease","volume":"18","author":"Fouad","year":"2024","journal-title":"Hepatol. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","article-title":"Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017\u20132020","volume":"22","author":"Kalligeros","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1053\/j.gastro.2023.06.008","article-title":"China\u2019s Fatty Liver Crisis: A Looming Public Health Emergency","volume":"165","author":"Yip","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1053\/j.gastro.2023.05.053","article-title":"Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study with 5.7 Million Adults in China","volume":"165","author":"Man","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Shen, Y., Wu, Y., Fu, M., Zhu, K., and Wang, J. (2023). Association between weight-adjusted-waist index with hepatic steatosis and liver fibrosis: A nationally representative cross-sectional study from NHANES 2017 to 2020. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1159055"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis\u2014Aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"(2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol., 81, 492\u2013542.","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: How is it different from NAFLD?","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.4254\/wjh.v15.i12.1253","article-title":"From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus","volume":"15","author":"Chen","year":"2023","journal-title":"World J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Shang","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"155999","DOI":"10.1016\/j.metabol.2024.155999","article-title":"Global burden of metabolic diseases, 1990\u20132021","volume":"160","author":"Zhang","year":"2024","journal-title":"Metabolism"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: A consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"155937","DOI":"10.1016\/j.metabol.2024.155937","article-title":"Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?","volume":"157","author":"Huttasch","year":"2024","journal-title":"Metabolism"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e12039","DOI":"10.1002\/ccs3.12039","article-title":"The signaling pathways in obesity-related complications","volume":"18","author":"Chandrasekaran","year":"2024","journal-title":"J. Cell Commun. Signal."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yanai, H., Adachi, H., Hakoshima, M., Iida, S., and Katsuyama, H. (2023). Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202309.1062.v1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13098-024-01259-2","article-title":"2024 UPDATE: The Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes","volume":"16","author":"Bertoluci","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ciardullo, S., Vergani, M., and Perseghin, G. (2023). Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment. J. Clin. Med., 12.","DOI":"10.3390\/jcm12175597"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Qi, X., Li, J., Caussy, C., Teng, G.J., and Loomba, R. (2024). Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Hepatology.","DOI":"10.1097\/HEP.0000000000000913"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients with Type 2 Diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","article-title":"Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease","volume":"36","author":"Bo","year":"2024","journal-title":"Cell Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Syed-Abdul, M.M. (2023). Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD). Metabolites, 14.","DOI":"10.3390\/metabo14010012"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/1744666X.2023.2294046","article-title":"The pathophysiology of MASLD: An immunometabolic perspective","volume":"20","author":"Grabherr","year":"2024","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101185","DOI":"10.1016\/j.jhepr.2024.101185","article-title":"Lipid metabolism in MASLD and MASH: From mechanism to the clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12944-024-02092-2","article-title":"Advances in management of metabolic dysfunction-associated steatotic liver disease: From mechanisms to therapeutics","volume":"23","author":"Jiang","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1210\/clinem\/dgab641","article-title":"Association of MAFLD with Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China","volume":"107","author":"Liang","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e240048","DOI":"10.1148\/rg.240048","article-title":"MASLD: What We Have Learned and Where We Need to Go-A Call to Action","volume":"44","author":"Martins","year":"2024","journal-title":"Radiographics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11427-024-2722-2","article-title":"Epidemiology of liver diseases: Global disease burden and forecasted research trends","volume":"68","author":"Xiao","year":"2024","journal-title":"Sci. China Life Sci."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Li, R., Li, H., Ye, X., and Qin, J. (2024). Metabolic Dysfunction-associated Steatotic Liver Disease is Becoming the Leading Driver of the Burden of Cirrhosis in China: Results From the Global Burden of Disease Study 2019. J. Clin. Gastroenterol.","DOI":"10.1097\/MCG.0000000000002055"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.medj.2024.03.017","article-title":"An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease","volume":"5","author":"Zhang","year":"2024","journal-title":"Med"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.giec.2024.06.004","article-title":"Approach to the Treatment of Children and Adolescents with Obesity","volume":"34","author":"Hegedus","year":"2024","journal-title":"Gastrointest. Endosc. Clin. N. Am."},{"key":"ref_38","first-page":"815","article-title":"Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism","volume":"12","author":"Feng","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Meyer, M., Schw\u00e4rzler, J., Jukic, A., and Tilg, H. (2024). Innate Immunity and MASLD. Biomolecules, 14.","DOI":"10.3390\/biom14040476"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/apt.17930","article-title":"Pathogenesis of MASLD and MASH\u2014Role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sergi, C.M. (2024). NAFLD (MASLD)\/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158462"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/pharmrev.123.001087","article-title":"Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies","volume":"76","author":"Kokkorakis","year":"2024","journal-title":"Pharmacol. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e2149641","DOI":"10.1002\/eji.202149641","article-title":"The \u201cDomino effect\u201d in MASLD: The inflammatory cascade of steatohepatitis","volume":"54","author":"Wensveen","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Allameh, A., Niayesh-Mehr, R., Aliarab, A., Sebastiani, G., and Pantopoulos, K. (2023). Oxidative Stress in Liver Pathophysiology and Disease. Antioxidants, 12.","DOI":"10.3390\/antiox12091653"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/gutjnl-2021-326874","article-title":"Current therapies and new developments in NASH","volume":"71","author":"Dufour","year":"2022","journal-title":"Gut"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1038\/s41467-024-50660-y","article-title":"A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma","volume":"15","author":"Jeong","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.dsx.2020.09.026","article-title":"Pathophysiological mechanisms underlying MAFLD","volume":"14","author":"Kuchay","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/hep.32562","article-title":"Endoplasmic reticulum stress in liver diseases","volume":"77","author":"Ajoolabady","year":"2023","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Cheng, Z., Chu, H., Seki, E., Lin, R., and Yang, L. (2024). Hepatocyte programmed cell death: The trigger for inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1431921"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41423-023-00983-5","article-title":"Mesenchymal stromal cells in hepatic fibrosis\/cirrhosis: From pathogenesis to treatment","volume":"20","author":"Yang","year":"2023","journal-title":"Cell Mol. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1499","DOI":"10.1002\/wsbm.1499","article-title":"Liver fibrosis: Pathophysiology and clinical implications","volume":"13","author":"Berumen","year":"2021","journal-title":"WIREs Mech. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"101231","DOI":"10.1016\/j.mam.2023.101231","article-title":"Liver fibrosis in NAFLD\/NASH: From pathophysiology towards diagnostic and therapeutic strategies","volume":"95","author":"Parola","year":"2024","journal-title":"Mol. Aspects Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S2468-1253(23)00438-7","article-title":"Pathophysiology and therapeutic options for cirrhotic portal hypertension","volume":"9","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40265-021-01493-2","article-title":"Pathophysiology and Management of Variceal Bleeding","volume":"81","author":"Alqahtani","year":"2021","journal-title":"Drugs"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jhep.2021.01.002","article-title":"Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction","volume":"75","author":"Engelmann","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Krag","year":"2021","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/j.jhep.2021.01.027","article-title":"Management of the major complications of cirrhosis: Beyond guidelines","volume":"75","author":"Francoz","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Carpi, S., Daniele, S., de Almeida, J.F.M., and Gabbia, D. (2024). Recent Advances in miRNA-Based Therapy for MASLD\/MASH and MASH-Associated HCC. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252212229"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Leyh, C., Coombes, J.D., Schmidt, H.H., Canbay, A., Manka, P.P., and Best, J. (2024). MASLD-Related HCC-Update on Pathogenesis and Current Treatment Options. J. Pers. Med., 14.","DOI":"10.3390\/jpm14040370"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Wang, X., Zhang, L., and Dong, B. (2024). Molecular mechanisms in MASLD\/MASH-related HCC. Hepatology.","DOI":"10.1097\/HEP.0000000000000786"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e0516","DOI":"10.1097\/HC9.0000000000000516","article-title":"The immune microenvironment of steatotic hepatocellular carcinoma: Current findings and future prospects","volume":"8","author":"Cheu","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e35338","DOI":"10.1016\/j.heliyon.2024.e35338","article-title":"From MASLD to HCC: What\u2019s in the middle?","volume":"10","author":"Provera","year":"2024","journal-title":"Heliyon"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Apostolo, D., Ferreira, L.L., Vincenzi, F., Vercellino, N., Minisini, R., Latini, F., Ferrari, B., Burlone, M.E., Pirisi, M., and Bellan, M. (2024). From MASH to HCC: The role of Gas6\/TAM receptors. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1332818"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"100416","DOI":"10.1016\/j.jhepr.2021.100416","article-title":"Cellular origins of regenerating liver and hepatocellular carcinoma","volume":"4","author":"Holczbauer","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2147\/JHC.S447848","article-title":"Macroscopic Characterization of Hepatocellular Carcinoma: An Underexploited Source of Prognostic Factors","volume":"11","author":"Gonvers","year":"2024","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2021.07.025","article-title":"Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention","volume":"75","author":"Lange","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.3748\/wjg.v30.i20.2633","article-title":"Impact of lifestyle interventions on pathogenesis of nonalcoholic fatty liver disease","volume":"30","author":"Ezzat","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2409210","DOI":"10.1080\/19490976.2024.2409210","article-title":"Entamoeba muris mitigates metabolic consequences of high-fat diet in mice","volume":"16","author":"Roy","year":"2024","journal-title":"Gut Microbes"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Iacob, S., Beckebaum, S., Iacob, R., Gheorghe, C., Cicinnati, V., Popescu, I., and Gheorghe, L. (2021). Genetic and Life Style Risk Factors for Recurrent Non-alcoholic Fatty Liver Disease Following Liver Transplantation. Front. Nutr., 8.","DOI":"10.3389\/fnut.2021.787430"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cld.2023.01.008","article-title":"Current Treatment Options, Including Diet, Exercise, and Medications: The Impact on Histology","volume":"27","author":"Noureddin","year":"2023","journal-title":"Clin. Liver Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., and Guo, J. (2022). Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1087260"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41392-022-01149-x","article-title":"Signaling pathways in obesity: Mechanisms and therapeutic interventions","volume":"7","author":"Wen","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4093\/dmj.2022.0048","article-title":"Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease","volume":"46","author":"Zhang","year":"2022","journal-title":"Diabetes Metab. J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/joim.13531","article-title":"Current treatment of non-alcoholic fatty liver disease","volume":"292","author":"Paternostro","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ueg2.12525","article-title":"Therapeutic management of metabolic dysfunction associated steatotic liver disease","volume":"12","author":"Zeng","year":"2024","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Beygi, M., Ahi, S., Zolghadri, S., and Stanek, A. (2024). Management of Metabolic-Associated Fatty Liver Disease\/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions. Nutrients, 16.","DOI":"10.3390\/nu16142220"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"goae029","DOI":"10.1093\/gastro\/goae029","article-title":"Advancements in pharmacological treatment of NAFLD\/MASLD: A focus on metabolic and liver-targeted interventions","volume":"12","author":"Ciardullo","year":"2024","journal-title":"Gastroenterol. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Butera, E., Termite, F., Esposto, G., Galasso, L., Mignini, I., Borriello, R., Ainora, M.E., Miele, L., Gasbarrini, A., and Zocco, M.A. (2024). Exploring the Role of Bempedoic Acid in Metabolic Dysfunction Associated Steatotic Liver Disease: Actual Evidence and Future Perspectives. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25136938"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tem.2024.04.010","article-title":"Revisiting liver metabolism through acetyl-CoA carboxylase inhibition","volume":"35","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","article-title":"New targets for NAFLD","volume":"3","author":"Parlati","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12964-023-01297-9","article-title":"Identification of novel SCD1 inhibitor alleviates nonalcoholic fatty liver disease: Critical role of liver-adipose axis","volume":"21","author":"Wang","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Longo, M., Paolini, E., Di Benedetto, P., Tomassini, E., Meroni, M., and Dongiovanni, P. (2024). DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25169074"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.tem.2022.08.001","article-title":"NAFLD and thyroid function: Pathophysiological and therapeutic considerations","volume":"33","author":"Hatziagelaki","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Ramanathan, R., Patwa, S.A., Ali, A.H., and Ibdah, J.A. (2023). Thyroid Hormone and Mitochondrial Dysfunction: Therapeutic Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Cells, 12.","DOI":"10.20944\/preprints202310.1615.v1"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/liv.15851","article-title":"Sodium-glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use","volume":"44","author":"Siafarikas","year":"2024","journal-title":"Liver Int."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Wu, D., and van de Graaf, S.F.J. (2024). Maladaptive regeneration and metabolic dysfunction associated steatotic liver disease: Common mechanisms and potential therapeutic targets. Biochem. Pharmacol., 227.","DOI":"10.1016\/j.bcp.2024.116437"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.tem.2023.10.002","article-title":"Mechanisms of hepatic fatty acid oxidation and ketogenesis during fasting","volume":"35","author":"Ruppert","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Wang, Y., Nakajima, T., Gonzalez, F.J., and Tanaka, N. (2020). PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062061"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13543784.2020.1681397","article-title":"A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?","volume":"29","author":"Tilg","year":"2020","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Burger, K., Jung, F., Baumann, A., Brandt, A., Staltner, R., S\u00e1nchez, V., and Bergheim, I. (2023). TNF\u03b1 is a key trigger of inflammation in diet-induced non-obese MASLD in mice. Redox Biol., 66.","DOI":"10.1016\/j.redox.2023.102870"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"101564","DOI":"10.1016\/j.xcrm.2024.101564","article-title":"Monocyte bioenergetics: An immunometabolic perspective in metabolic dysfunction-associated steatohepatitis","volume":"5","author":"Sangineto","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/15548627.2021.1895658","article-title":"The m\u00e9nage \u00e0 trois of autophagy, lipid droplets and liver disease","volume":"18","author":"Hunter","year":"2022","journal-title":"Autophagy"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e10124","DOI":"10.15252\/emmm.201810124","article-title":"Liver ASK1 protects from non-alcoholic fatty liver disease and fibrosis","volume":"11","author":"Challa","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.freeradbiomed.2017.07.020","article-title":"Oxidative and ER stress-dependent ASK1 activation in steatotic hepatocytes and Kupffer cells sensitizes mice fatty liver to ischemia\/reperfusion injury","volume":"112","author":"Imarisio","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1038\/s41401-024-01329-1","article-title":"FXR activation remodels hepatic and intestinal transcriptional landscapes in metabolic dysfunction-associated steatohepatitis","volume":"45","author":"Wen","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1136\/gutjnl-2017-313712","article-title":"What if Prometheus had steatosis? Potential use of FGF19 to promote regeneration of the fatty liver","volume":"66","author":"Brown","year":"2017","journal-title":"Gut"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.yexcr.2017.05.006","article-title":"Fatty liver and FGF21 physiology","volume":"360","year":"2017","journal-title":"Exp. Cell Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"100524","DOI":"10.1016\/j.jhepr.2022.100524","article-title":"Understanding the cellular interactome of non-alcoholic fatty liver disease","volume":"4","author":"Wallace","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1369\/0022155415627681","article-title":"TGF-\u03b2\/SMAD Pathway and Its Regulation in Hepatic Fibrosis","volume":"64","author":"Xu","year":"2016","journal-title":"J. Histochem. Cytochem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cbi.2018.07.008","article-title":"New insights into TGF-\u03b2\/Smad signaling in tissue fibrosis","volume":"292","author":"Hu","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","article-title":"Hepatic stellate cells as key target in liver fibrosis","volume":"121","author":"Higashi","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41573-019-0040-5","article-title":"Targeting metabolic dysregulation for fibrosis therapy","volume":"19","author":"Zhao","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","article-title":"Trends in insulin resistance: Insights into mechanisms and therapeutic strategy","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_111","first-page":"691","article-title":"MASLD: A systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1111\/apt.17866","article-title":"Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity","volume":"59","author":"Chan","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2304157","DOI":"10.1080\/19490976.2024.2304157","article-title":"Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus","volume":"16","author":"Forlano","year":"2024","journal-title":"Gut Microbes"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1111\/liv.16016","article-title":"The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes","volume":"44","author":"Riley","year":"2024","journal-title":"Liver Int."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: Two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/hep.29246","article-title":"Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study","volume":"66","author":"Stiede","year":"2017","journal-title":"Hepatology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/dom.14272","article-title":"Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials","volume":"23","author":"Beysen","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: A multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e0425","DOI":"10.1097\/HC9.0000000000000425","article-title":"Potential utility of l-carnitine for preventing liver tumors derived from metabolic dysfunction-associated steatohepatitis","volume":"8","author":"Lyu","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1038\/s41467-023-42162-0","article-title":"ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib\/IIa trial","volume":"14","author":"Hu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(20)30186-2","article-title":"Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: A multicentre, double-blind, randomised, placebo-controlled phase 2 trial","volume":"5","author":"Loomba","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/hep.24544","article-title":"Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial","volume":"54","author":"Zein","year":"2011","journal-title":"Hepatology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/HEP.0000000000000855","article-title":"Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial","volume":"80","author":"Cheung","year":"2024","journal-title":"Hepatology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"108610","DOI":"10.1016\/j.jdiacomp.2023.108610","article-title":"Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"37","author":"Shi","year":"2023","journal-title":"J. Diabetes Complicat."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin Improves the Hepatic Outcomes of Patients with Diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1210\/clinem\/dgad249","article-title":"Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients with Diabetes Mellitus: New Insights From CANVAS","volume":"108","author":"Borisov","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk","volume":"387","author":"Glynn","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-Term Pioglitazone Treatment for Patients with Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.cgh.2023.01.018","article-title":"Saroglitazar, a Dual PPAR \u03b1\/\u03b3 Agonist, Improves Atherogenic Dyslipidemia in Patients with Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis","volume":"21","author":"Siddiqui","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-\u03b1 and -\u03b4, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MPG.0000000000003796","article-title":"An Open Label, Randomized, Multicenter Study of Elafibranor in Children with Nonalcoholic Steatohepatitis","volume":"77","author":"Goyal","year":"2023","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Lawitz","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/s42255-023-00938-0","article-title":"Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes","volume":"5","author":"Parker","year":"2023","journal-title":"Nat. Metab."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: Randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"100676","DOI":"10.1016\/j.jlr.2024.100676","article-title":"Targeting acetyl-CoA carboxylases for the treatment of MASLD","volume":"65","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1124\/dmd.123.001449","article-title":"Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5\/ACLY Signaling Axis","volume":"51","author":"Sun","year":"2023","journal-title":"Drug Metab. Dispos."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of Bempedoic Acid Administration with Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients with Hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e024531","DOI":"10.1161\/JAHA.121.024531","article-title":"Factors Associated with Enhanced Low-Density Lipoprotein Cholesterol Lowering with Bempedoic Acid","volume":"11","author":"Ballantyne","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"101193","DOI":"10.1016\/j.xcrm.2023.101193","article-title":"Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice","volume":"4","author":"Desjardins","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Zhang, S., Ren, X., Zhang, B., Lan, T., and Liu, B. (2024). A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action. Molecules, 29.","DOI":"10.3390\/molecules29081859"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4068\/cmj.2024.60.1.13","article-title":"Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients","volume":"60","author":"Eslami","year":"2024","journal-title":"Chonnam Med. J."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Ayada, I., van Kleef, L.A., Zhang, H., Liu, K., Li, P., Abozaid, Y.J., Lavrijsen, M., Janssen, H.L.A., van der Laan, L.J.W., and Ghanbari, M. (2023). Dissecting the multifaceted impact of statin use on fatty liver disease: A multidimensional study. EBioMedicine, 87.","DOI":"10.1016\/j.ebiom.2022.104392"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"101816","DOI":"10.1016\/j.clinre.2021.101816","article-title":"Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis","volume":"46","author":"Fatima","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/MJT.0000000000001499","article-title":"Statins for the Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis","volume":"30","author":"Dai","year":"2023","journal-title":"Am. J. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/jgh.16495","article-title":"Statin use in cirrhosis and its association with incidence of portal vein thrombosis","volume":"39","author":"Amjad","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","article-title":"Thyroid hormone receptor-\u03b2 analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"82","author":"Ratziu","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s13679-024-00582-z","article-title":"Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals","volume":"13","author":"Au","year":"2024","journal-title":"Curr. Obes. Rep."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Radosavljevic, T., Brankovic, M., Samardzic, J., Djureti\u0107, J., Vukicevic, D., Vucevic, D., and Jakovljevic, V. (2024). Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches. Antioxidants, 13.","DOI":"10.3390\/antiox13080906"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.17734","article-title":"Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis","volume":"59","author":"Harrison","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cellsig.2018.06.005","article-title":"Role of cAMP and phosphodiesterase signaling in liver health and disease","volume":"49","author":"Wahlang","year":"2018","journal-title":"Cell Signal."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/13543784.2021.1900822","article-title":"Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: A double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study","volume":"30","author":"Zhu","year":"2021","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"111688","DOI":"10.1016\/j.diabres.2024.111688","article-title":"MASLD\/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists","volume":"212","author":"Cooreman","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tem.2022.03.005","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease","volume":"33","author":"Moon","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Alfieri, C.M., Molinari, P., Cinque, F., Vettoretti, S., Cespiati, A., Bignamini, D., Nardelli, L., Fracanzani, A.L., Castellano, G., and Lombardi, R. (2024). What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147728"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eprac.2024.11.017","article-title":"Comparison of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter protein-2 inhibitors on treating metabolic dysfunction-associated steatotic liver disease or metabolic dysfunction-associated steatohepatitis: Systematic review and network meta-analysis of randomised controlled trials","volume":"31","author":"Xu","year":"2025","journal-title":"Endocr. Pract."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/dom.15006","article-title":"Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study","volume":"25","author":"Hiruma","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4314\/ahs.v23i2.48","article-title":"Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials","volume":"23","author":"Hu","year":"2023","journal-title":"Afr. Health Sci."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/jdi.14246","article-title":"Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD","volume":"15","author":"Ito","year":"2024","journal-title":"J. Diabetes Investig."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdi.12980","article-title":"Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"10","author":"Inoue","year":"2019","journal-title":"J. Diabetes Investig."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"108391","DOI":"10.1016\/j.pharmthera.2023.108391","article-title":"PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets","volume":"245","author":"Chen","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/13543776.2024.2332661","article-title":"Peroxisome Proliferator-Activated Receptor agonists and antagonists: An updated patent review (2020\u20132023)","volume":"34","author":"Granese","year":"2024","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"156043","DOI":"10.1016\/j.metabol.2024.156043","article-title":"Comparative efficacy of THR-\u03b2 agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis","volume":"161","author":"Lin","year":"2024","journal-title":"Metabolism"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: A collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/MEG.0000000000002766","article-title":"Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: The influence of alcohol consumption","volume":"36","author":"Iwasa","year":"2024","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/jgh3.12650","article-title":"Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score","volume":"5","author":"Hatanaka","year":"2021","journal-title":"JGH Open"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12933-024-02305-z","article-title":"Lessons from PROMINENT and prospects for pemafibrate","volume":"23","author":"Fruchart","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Yanai, H., Katsuyama, H., and Hakoshima, M. (2022). Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor \u03b1 Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020401"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s12072-022-10453-1","article-title":"Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: A multicenter study","volume":"17","author":"Morishita","year":"2023","journal-title":"Hepatol. Int."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"108984","DOI":"10.1016\/j.diabres.2021.108984","article-title":"Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: Clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial","volume":"178","author":"Russo","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Lian, J., and Fu, J. (2021). Pioglitazone for NAFLD Patients with Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.615409"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065\u2014Deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"155912","DOI":"10.1016\/j.metabol.2024.155912","article-title":"Deciphering the molecular pathways of saroglitazar: A dual PPAR \u03b1\/\u03b3 agonist for managing metabolic NAFLD","volume":"155","author":"Ezhilarasan","year":"2024","journal-title":"Metabolism"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jhep.2023.10.038","article-title":"NIS2+(TM) as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials","volume":"80","author":"Ratziu","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1021\/acs.jmedchem.1c02002","article-title":"Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPAR\u03b1\/\u03b4 Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis","volume":"65","author":"Feng","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","article-title":"Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications","volume":"166","author":"Mirza","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Kamata, S., Honda, A., and Ishii, I. (2023). Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease. Biomolecules, 13.","DOI":"10.3390\/biom13081264"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1152\/physrev.00028.2023","article-title":"Hepatic glucagon action: Beyond glucose mobilization","volume":"104","author":"Kajani","year":"2024","journal-title":"Physiol. Rev."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"111675","DOI":"10.1016\/j.diabres.2024.111675","article-title":"Incretin-based investigational therapies for the treatment of MASLD\/MASH","volume":"211","author":"Brouwers","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.cgh.2024.01.032","article-title":"The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis","volume":"22","author":"Abushamat","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.3748\/wjg.v30.i30.3541","article-title":"Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Soresi","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"e16150","DOI":"10.1111\/liv.16150","article-title":"Genetic Evidence for GLP-1 and GIP Receptors as Targets for Treatment and Prevention of MASLD\/MASH","volume":"45","author":"Yan","year":"2025","journal-title":"Liver Int."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/HEP.0000000000000723","article-title":"Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis","volume":"80","author":"Ratziu","year":"2024","journal-title":"Hepatology"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4 mg in Participants with Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/apt.18042","article-title":"Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures","volume":"60","author":"Vuppalanchi","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"108487","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/hep4.1993","article-title":"Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial","volume":"6","author":"Yoneda","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/dom.13907","article-title":"Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes","volume":"22","author":"Gastaldelli","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"102279","DOI":"10.1016\/j.clinre.2023.102279","article-title":"Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"48","author":"Shargh","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Lin, Y.H., Zhang, Z.J., Zhong, J.Q., Wang, Z.Y., Peng, Y.T., Lin, Y.M., Zhang, H.P., and Tian, J.Q. (2024). Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0302155"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Nonaka, H., Ohue-Kitano, R., Masujima, Y., Igarashi, M., and Kimura, I. (2022). Dietary Medium-Chain Triglyceride Decanoate Affects Glucose Homeostasis Through GPR84-Mediated GLP-1 Secretion in Mice. Front. Nutr., 9.","DOI":"10.3389\/fnut.2022.848450"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cct.2016.02.012","article-title":"Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design","volume":"47","author":"Friedman","year":"2016","journal-title":"Contemp. Clin. Trials"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"105889","DOI":"10.1016\/j.cct.2019.105889","article-title":"A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients with Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","article-title":"A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes","volume":"12","author":"Harrison","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in Patients with Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study","volume":"22","author":"Loomba","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in Patients with Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): A randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/jcpt.12784","article-title":"The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial","volume":"44","author":"Amirkhizi","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Zhang, C., and Yang, M. (2021). Current Options and Future Directions for NAFLD and NASH Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147571"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/14728222.2024.2366880","article-title":"Fatty liver disease: Time to target CCR5?","volume":"28","author":"Brata","year":"2024","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"e0335","DOI":"10.1097\/HC9.0000000000000335","article-title":"Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis","volume":"8","author":"Francque","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS20230934","article-title":"Bile salt signaling and bile salt-based therapies in cardiometabolic disease","volume":"138","author":"Groenen","year":"2024","journal-title":"Clin. Sci."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","article-title":"Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study","volume":"78","author":"Anstee","year":"2023","journal-title":"Hepatology"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2468-1253(19)30184-0","article-title":"Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: A double-blind, randomised, placebo-controlled, phase 2 dose-finding trial","volume":"4","author":"Traussnigg","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"101094","DOI":"10.1016\/j.plipres.2021.101094","article-title":"Bile acids and their receptors in metabolic disorders","volume":"82","author":"Fiorucci","year":"2021","journal-title":"Prog. Lipid Res."},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Li, X., Zheng, K., Liu, L., Zhang, T., Gu, W., Hou, X., Geng, J., and Song, G. (2024). Relationship of postprandial fibroblast growth factor 21 with lipids, inflammation and metabolic dysfunction-associated fatty liver disease during oral fat tolerance test. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1343853"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S2468-1253(23)00285-6","article-title":"Efruxifermin in non-alcoholic steatohepatitis","volume":"8","author":"Mahgoub","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"100563","DOI":"10.1016\/j.jhepr.2022.100563","article-title":"A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis","volume":"5","author":"Harrison","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): A multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","article-title":"Safety and Efficacy of Efruxifermin in Combination with a GLP-1 Receptor Agonist in Patients with NASH\/MASH and Type 2 Diabetes in a Randomized Phase 2 Study","volume":"23","author":"Harrison","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatology"},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Gensluckner, S., Wernly, B., Datz, C., and Aigner, E. (2024). Iron, Oxidative Stress, and Metabolic Dysfunction\u2014Associated Steatotic Liver Disease. Antioxidants, 13.","DOI":"10.3390\/antiox13020208"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"e23466","DOI":"10.1096\/fj.202302447R","article-title":"Oxidative stress in metabolic dysfunction-associated steatotic liver disease (MASLD): How does the animal model resemble human disease?","volume":"38","author":"Jakubek","year":"2024","journal-title":"FASEB J."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/iub.1991","article-title":"Role of vitamin E in nonalcoholic fatty liver disease","volume":"71","author":"Nagashimada","year":"2019","journal-title":"IUBMB Life"},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Podszun, M.C., and Frank, J. (2021). Impact of vitamin E on redox biomarkers in non-alcoholic fatty liver disease. Redox Biol., 42.","DOI":"10.1016\/j.redox.2021.101937"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/MCO.0b013e328357f747","article-title":"Vitamin E and nonalcoholic fatty liver disease","volume":"15","author":"Pacana","year":"2012","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"102866","DOI":"10.1016\/j.ctim.2022.102866","article-title":"Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: A randomized double-blind active-controlled trial","volume":"70","author":"Pervez","year":"2022","journal-title":"Complement. Ther. Med."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: Comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_256","doi-asserted-by":"crossref","unstructured":"Vogli, S., Naska, A., Marinos, G., Kasdagli, M.I., and Orfanos, P. (2023). The Effect of Vitamin E Supplementation on Serum Aminotransferases in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis. Nutrients, 15.","DOI":"10.3390\/nu15173733"},{"key":"ref_257","doi-asserted-by":"crossref","unstructured":"Longhitano, L., Tibullo, D., Zuppelli, T., Ronsisvalle, S., La Spina, E., Nicolosi, A., Antoci, M., Sipala, F.M., Galvano, F., and Currenti, W. (2024). (+)Alpha-Lipoic Acid Regulates Lipid Metabolism Gene Expression and Lipidic Profile in a Cellular Model of Fatty Acid Overload. Front. Biosci., 29.","DOI":"10.31083\/j.fbl2906209"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/j.1478-3231.2012.02857.x","article-title":"\u03b1-lipoic acid prevents non-alcoholic fatty liver disease in OLETF rats","volume":"32","author":"Jung","year":"2012","journal-title":"Liver Int."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1039\/C9FO00449A","article-title":"Oral \u03b1-lipoic acid supplementation in patients with non-alcoholic fatty liver disease: Effects on adipokines and liver histology features","volume":"10","author":"Rahmanabadi","year":"2019","journal-title":"Food Funct."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"2341701","DOI":"10.1080\/09513590.2024.2341701","article-title":"Alpha lipoic acid administration improved both peripheral sensitivity to insulin and liver clearance of insulin reducing potential risk of diabetes and nonalcoholic fatty liver disease in overweight\/obese PCOS patients","volume":"40","author":"Genazzani","year":"2024","journal-title":"Gynecol. Endocrinol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4062\/biomolther.2020.016","article-title":"Selonsertib Inhibits Liver Fibrosis via Downregulation of ASK1\/ MAPK Pathway of Hepatic Stellate Cells","volume":"28","author":"Yoon","year":"2020","journal-title":"Biomol. Ther."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jcmgh.2023.02.010","article-title":"Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease","volume":"15","author":"Wiering","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/hep.32181","article-title":"BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial","volume":"75","author":"Lawitz","year":"2022","journal-title":"Hepatology"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41467-022-35637-z","article-title":"Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis","volume":"14","author":"Han","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/liv.15915","article-title":"Targeted inhibition of autophagy in hepatic stellate cells by hydroxychloroquine: An effective therapeutic approach for the treatment of liver fibrosis","volume":"44","author":"Hou","year":"2024","journal-title":"Liver Int."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1021\/acsami.3c12776","article-title":"Integrin-Targeted Theranostic Nanoparticles for Clinical MRI-Traceable Treatment of Liver Fibrosis","volume":"16","author":"Hu","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"14852","DOI":"10.1021\/acsnano.3c03217","article-title":"Nanoparticle-Mediated RNA Therapy Attenuates Nonalcoholic Steatohepatitis and Related Fibrosis by Targeting Activated Hepatic Stellate Cells","volume":"17","author":"Zhang","year":"2023","journal-title":"ACS Nano"},{"key":"ref_268","first-page":"569","article-title":"A boronate-based modular assembly nanosystem to block the undesirable crosstalk between hepatic stellate cells and Kupffer cells","volume":"25","author":"Jia","year":"2023","journal-title":"Bioact. Mater."},{"key":"ref_269","doi-asserted-by":"crossref","unstructured":"Wu, P., Luo, X., Wu, H., Zhang, Q., Dai, Y., and Sun, M. (2020). Efficient and targeted chemo-gene delivery with self-assembled fluoro-nanoparticles for liver fibrosis therapy and recurrence. Biomaterials, 261.","DOI":"10.1016\/j.biomaterials.2020.120311"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.actbio.2022.08.065","article-title":"Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy","volume":"152","author":"Zhou","year":"2022","journal-title":"Acta Biomater."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"117964","DOI":"10.1016\/j.carbpol.2021.117964","article-title":"Co-encapsulation of collagenase type I and silibinin in chondroitin sulfate coated multilayered nanoparticles for targeted treatment of liver fibrosis","volume":"263","author":"Luo","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"e2212206","DOI":"10.1002\/adma.202212206","article-title":"Restoration of Sinusoid Fenestrae Followed by Targeted Nanoassembly Delivery of an Anti-Fibrotic Agent Improves Treatment Efficacy in Liver Fibrosis","volume":"35","author":"Li","year":"2023","journal-title":"Adv. Mater."},{"key":"ref_273","doi-asserted-by":"crossref","unstructured":"Peng, W., Cheng, S., Bao, Z., Wang, Y., Zhou, W., Wang, J., Yang, Q., Chen, C., and Wang, W. (2021). Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis. Biomed. Pharmacother., 137.","DOI":"10.1016\/j.biopha.2021.111342"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"101091","DOI":"10.1016\/j.jhepr.2024.101091","article-title":"Durability and on-treatment predictors of recompensation in entecavir-treated patients with hepatitis B and decompensated cirrhosis","volume":"6","author":"Deng","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41395-018-0185-6","article-title":"Refractory Ascites in Liver Cirrhosis","volume":"114","author":"Adebayo","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cld.2024.03.002","article-title":"Pharmacologic Treatment of Portal Hypertension","volume":"28","author":"Wong","year":"2024","journal-title":"Clin. Liver Dis."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1939-1676.2011.00691.x","article-title":"Portal hypertension: Pathophysiology, diagnosis, and treatment","volume":"25","author":"Buob","year":"2011","journal-title":"J. Vet. Intern. Med."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.cgh.2023.03.019","article-title":"Update in the Treatment of the Complications of Cirrhosis","volume":"21","author":"Abraldes","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_279","doi-asserted-by":"crossref","unstructured":"Lu, F., Th\u00e9venot, T., Mancuso, A., Li, Y., Liu, L., and Qi, X. (2023). Editorial: Treatment and prognostic assessment of liver cirrhosis and its complications. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1359036"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.cgh.2022.04.034","article-title":"Hepatic Encephalopathy: Current and Emerging Treatment Modalities","volume":"20","author":"Fallahzadeh","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/17474124.2023.2183386","article-title":"Hepatic encephalopathy\u2014Recent advances in treatment and diagnosis","volume":"17","author":"Nardelli","year":"2023","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.mcna.2023.03.009","article-title":"Hepatorenal Syndrome: Pathophysiology, Diagnosis, and Treatment","volume":"107","author":"Belcher","year":"2023","journal-title":"Med. Clin. N. Am."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome","volume":"384","author":"Wong","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2021.08.016","article-title":"Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward","volume":"79","author":"Belcher","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_285","doi-asserted-by":"crossref","unstructured":"Badura, K., Fr\u0105k, W., Hajdys, J., Majchrowicz, G., M\u0142ynarska, E., Rysz, J., and Franczyk, B. (2023). Hepatorenal Syndrome-Novel Insights into Diagnostics and Treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242417469"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/bjs.9849","article-title":"Surgical treatment for portal hypertension","volume":"102","author":"Mercado","year":"2015","journal-title":"Br. J. Surg."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1053\/j.gastro.2016.03.015","article-title":"A New Treatment for Portal Hypertension?","volume":"150","author":"Rockey","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_288","doi-asserted-by":"crossref","unstructured":"Melandro, F., Parisse, S., Ginanni Corradini, S., Cardinale, V., Ferri, F., Merli, M., Alvaro, D., Pugliese, F., Rossi, M., and Mennini, G. (2024). Transjugular Intrahepatic Portosystemic Shunt as a Bridge to Abdominal Surgery in Cirrhosis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13082213"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMra2200923","article-title":"Liver Transplantation","volume":"389","author":"Lucey","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jhep.2023.01.030","article-title":"Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation","volume":"78","author":"Pageaux","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S2468-1253(23)00363-1","article-title":"Liver transplantation for acute-on-chronic liver failure","volume":"9","author":"Artru","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S2468-1253(22)00268-0","article-title":"Enhanced recovery for liver transplantation: Recommendations from the 2022 International Liver Transplantation Society consensus conference","volume":"8","author":"Pollok","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: A multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40265-018-0932-4","article-title":"Regorafenib: A Review in Hepatocellular Carcinoma","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1002\/onco.13566","article-title":"FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma","volume":"26","author":"Nair","year":"2021","journal-title":"Oncologist"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet. Oncol."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1158\/1078-0432.CCR-20-4706","article-title":"Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma","volume":"27","author":"Castet","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jconrel.2024.08.044","article-title":"Liver-targeting chimeras as a potential modality for the treatment of liver diseases","volume":"374","author":"Chen","year":"2024","journal-title":"J. Control. Release"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/hep.30326","article-title":"Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma","volume":"70","author":"Fu","year":"2019","journal-title":"Hepatology"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"eabb6282","DOI":"10.1126\/scitranslmed.abb6282","article-title":"Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate","volume":"13","author":"Kong","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_307","doi-asserted-by":"crossref","unstructured":"Stemmer, S.M., Manojlovic, N.S., Marinca, M.V., Petrov, P., Cherciu, N., Ganea, D., Ciuleanu, T.E., Pusca, I.A., Beg, M.S., and Purcell, W.T. (2021). Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial. Cancers, 13.","DOI":"10.3390\/cancers13020187"},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","article-title":"Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies","volume":"67","author":"Bruix","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.7150\/thno.54822","article-title":"Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma","volume":"11","author":"Kong","year":"2021","journal-title":"Theranostics"},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/gutjnl-2018-316408","article-title":"Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial","volume":"68","author":"Pinyol","year":"2019","journal-title":"Gut"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40265-019-01116-x","article-title":"Lenvatinib: A Review in Hepatocellular Carcinoma","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","article-title":"REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: An analysis of Japanese subset","volume":"55","author":"Yamashita","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.20.02672","article-title":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline","volume":"38","author":"Gordan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"e007366","DOI":"10.1136\/jitc-2023-007366","article-title":"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: A single-arm, phase II trial","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2468-1253(21)00110-2","article-title":"Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: Patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial","volume":"6","author":"Vogel","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s40265-021-01603-0","article-title":"Donafenib: First Approval","volume":"81","author":"Keam","year":"2021","journal-title":"Drugs"},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"17588359241258394","DOI":"10.1177\/17588359241258394","article-title":"Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: A real-world experience","volume":"16","author":"Zhang","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"737","DOI":"10.21037\/hbsn-21-304","article-title":"Donafenib as a first-line monotherapy for advanced hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial","volume":"39","author":"Qin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): A multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"e000453","DOI":"10.1136\/jitc-2019-000453","article-title":"Phase IA\/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors","volume":"8","author":"Desai","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jceh.2022.07.003","article-title":"Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma","volume":"12","author":"Roy","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"592","DOI":"10.21037\/hbsn-22-143","article-title":"Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients with Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I\/II Study","volume":"39","author":"Kelley","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2468-1253(23)00454-5","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): Final results of a randomised phase 3 study","volume":"9","author":"Yau","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jtho.2023.12.023","article-title":"Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC with Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial","volume":"19","author":"Yang","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1200\/JCO-24-01326","article-title":"First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial","volume":"43","author":"Marth","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): A randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_334","doi-asserted-by":"crossref","unstructured":"Hsu, Y.C., Lin, P.T., Teng, W., Hsieh, Y.C., Chen, W.T., Su, C.W., Wang, C.T., Chai, P.M., Lin, C.C., and Lin, C.Y. (2024). Comparing Lenvatinib\/Pembrolizumab with Atezolizumab\/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis. Cancers, 16.","DOI":"10.3390\/cancers16203458"},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s11523-024-01091-8","article-title":"A Phase 1a\/1b Dose Escalation\/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma","volume":"19","author":"Gong","year":"2024","journal-title":"Target. Oncol."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/onco.13819","article-title":"FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib","volume":"26","author":"Saung","year":"2021","journal-title":"Oncologist"},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: A randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_340","doi-asserted-by":"crossref","unstructured":"Han, C., Ye, S., Hu, C., Shen, L., Qin, Q., Bai, Y., Yang, S., Bai, C., Zang, A., and Jiao, S. (2021). Clinical Activity and Safety of Penpulimab (Anti-PD-1) with Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib\/II Trial (AK105-203). Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.684867"},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"16191","DOI":"10.1007\/s00432-023-05342-5","article-title":"Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis","volume":"149","author":"Liu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1158\/1078-0432.CCR-24-0006","article-title":"Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial","volume":"30","author":"Chen","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1093\/oncolo\/oyad169","article-title":"Anlotinib Combined with Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study","volume":"28","author":"Zhang","year":"2023","journal-title":"Oncologist"},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","article-title":"Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial","volume":"174","author":"Lai","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"17588359211002720","DOI":"10.1177\/17588359211002720","article-title":"Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma","volume":"13","author":"He","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"10141","DOI":"10.7150\/thno.46985","article-title":"The peptide PROTAC modality: A novel strategy for targeted protein ubiquitination","volume":"10","author":"Jin","year":"2020","journal-title":"Theranostics"},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"D1367","DOI":"10.1093\/nar\/gkac946","article-title":"PROTAC-DB 2.0: An updated database of PROTACs","volume":"51","author":"Weng","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted protein degradation: Elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"114290","DOI":"10.1016\/j.ejmech.2022.114290","article-title":"The state of the art of PROTAC technologies for drug discovery","volume":"235","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_352","doi-asserted-by":"crossref","unstructured":"Qi, S.M., Dong, J., Xu, Z.Y., Cheng, X.D., Zhang, W.D., and Qin, J.J. (2021). PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.692574"},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","article-title":"The antibody-drug conjugate landscape","volume":"23","author":"Flynn","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1097\/JS9.0000000000001748","article-title":"Antibody drug conjugate, a level-up version of monoclonal antibody?","volume":"110","author":"Yang","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"2229101","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody-drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"MAbs"},{"key":"ref_357","doi-asserted-by":"crossref","unstructured":"Wang, W., Zhou, Y., Li, W., Quan, C., and Li, Y. (2024). Claudins and hepatocellular carcinoma. Biomed. Pharmacother., 171.","DOI":"10.1016\/j.biopha.2023.116109"},{"key":"ref_358","doi-asserted-by":"crossref","unstructured":"Etzion, O., Bareket-Samish, A., Yardeni, D., and Fishman, P. (2024). Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma. Biomedicines, 12.","DOI":"10.3390\/biomedicines12040848"},{"key":"ref_359","doi-asserted-by":"crossref","unstructured":"Wicks, J.S., Dale, B.S., Ruffolo, L., Pack, L.J., Dunne, R., Laryea, M.A., Hernandez-Alejandro, R., and Sharma, A.K. (2023). Comparable and Complimentary Modalities for Treatment of Small-Sized HCC: Surgical Resection, Radiofrequency Ablation, and Microwave Ablation. J. Clin. Med., 12.","DOI":"10.3390\/jcm12155006"},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: Trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_361","doi-asserted-by":"crossref","unstructured":"Chakraborty, E., and Sarkar, D. (2022). Emerging Therapies for Hepatocellular Carcinoma (HCC). Cancers, 14.","DOI":"10.3390\/cancers14112798"},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_363","doi-asserted-by":"crossref","unstructured":"Kimura, T., Fujiwara, T., Kameoka, T., Adachi, Y., and Kariya, S. (2022). The Current Role of Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma (HCC). Cancers, 14.","DOI":"10.3390\/cancers14184383"},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/hep.32054","article-title":"Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next?","volume":"74","author":"Sangro","year":"2021","journal-title":"Hepatology"},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","article-title":"Precision treatment in advanced hepatocellular carcinoma","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_366","doi-asserted-by":"crossref","unstructured":"Liu, J., Sun, J., Yu, J., Chen, H., Zhang, D., Zhang, T., Ma, Y., Zou, C., Zhang, Z., and Ma, L. (2023). Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism. npj Biofilms Microbiomes, 9.","DOI":"10.1038\/s41522-023-00399-z"},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1053\/j.gastro.2020.01.049","article-title":"Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?","volume":"158","author":"Warmbrunn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_368","doi-asserted-by":"crossref","unstructured":"Xiang, H., Sun, D., Liu, X., She, Z.G., and Chen, Y. (2022). The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.812610"},{"key":"ref_369","doi-asserted-by":"crossref","unstructured":"Zhou, X., Zhang, X., and Yu, J. (2024). Gut mycobiome in metabolic diseases: Mechanisms and clinical implication. Biomed. J., 47.","DOI":"10.1016\/j.bj.2023.100625"},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41423-020-00592-6","article-title":"Gut microbiome, liver immunology, and liver diseases","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: Pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab."},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"2331460","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the barriers: The role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)","volume":"16","author":"Cubero","year":"2024","journal-title":"Gut Microbes"},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"11240","DOI":"10.12998\/wjcc.v10.i31.11240","article-title":"Intestinal microbiota in the treatment of metabolically associated fatty liver disease","volume":"10","author":"Wang","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s11154-023-09843-z","article-title":"Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies","volume":"24","author":"Jayachandran","year":"2023","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"64","DOI":"10.14715\/cmb\/2021.67.5.9","article-title":"Effects of Clostridium butyricum Capsules Combined with Rosuvastatin on Intestinal Flora, Lipid Metabolism, Liver Function and Inflammation in NAFLD Patients","volume":"68","author":"Zhu","year":"2022","journal-title":"Cell. Mol. Biol."},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1017\/S0007114517000204","article-title":"Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: A pilot, randomised, double-blind, placebo-controlled, clinical trial","volume":"117","author":"Mofidi","year":"2017","journal-title":"Br. J. Nutr."},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial","volume":"58","author":"Bomhof","year":"2019","journal-title":"Eur. J. Nutr."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.cmet.2023.08.002","article-title":"Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations","volume":"35","author":"Ni","year":"2023","journal-title":"Cell Metab."},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"01","DOI":"10.35946\/arcr.v44.1.01","article-title":"Gut-Liver-Brain Axis and Alcohol Use Disorder: Treatment Potential of Fecal Microbiota Transplantation","volume":"44","author":"Wolstenholme","year":"2024","journal-title":"Alcohol. Res."},{"key":"ref_380","doi-asserted-by":"crossref","unstructured":"Xue, L., Deng, Z., Luo, W., He, X., and Chen, Y. (2022). Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Front. Cell Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.759306"},{"key":"ref_381","doi-asserted-by":"crossref","unstructured":"Zeng, C., Wan, S.R., Guo, M., Tan, X.Z., Zeng, Y., Wu, Q., Xie, J.J., Yan, P., Long, Y., and Zheng, L. (2024). Fecal virome transplantation: A promising strategy for the treatment of metabolic diseases. Biomed. Pharmacother., 177.","DOI":"10.1016\/j.biopha.2024.117065"},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"106621","DOI":"10.1016\/j.phrs.2022.106621","article-title":"Diosgenin alleviates nonalcoholic steatohepatitis through affecting liver-gut circulation","volume":"187","author":"Yan","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_383","doi-asserted-by":"crossref","unstructured":"Feng, J., Cheng, F., Lv, Y., Yu, Z., Zhang, M., Chen, L., Xu, M., and Guan, F. (2023). Effects of (20 R)-Panaxadiol on NAFLD using non-targeted metabolomics in stool. J. Pharm. Biomed. Anal., 234.","DOI":"10.1016\/j.jpba.2023.115555"},{"key":"ref_384","doi-asserted-by":"crossref","unstructured":"Yan, J., Nie, Y., Liu, Y., Li, J., Wu, L., Chen, Z., and He, B. (2022). Yiqi-Bushen-Tiaozhi Recipe Attenuated High-Fat and High-Fructose Diet Induced Nonalcoholic Steatohepatitis in Mice via Gut Microbiota. Front. Cell Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.824597"},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"156026","DOI":"10.1016\/j.phymed.2024.156026","article-title":"Multi-omics joint analysis reveals that the Miao medicine Yindanxinnaotong formula attenuates non-alcoholic fatty liver disease","volume":"135","author":"Huang","year":"2024","journal-title":"Phytomedicine"},{"key":"ref_386","doi-asserted-by":"crossref","unstructured":"Zhou, R., He, D., Xie, J., Zhou, Q., Zeng, H., Li, H., and Huang, L. (2021). The Synergistic Effects of Polysaccharides and Ginsenosides From American Ginseng (Panax quinquefolius L.) Ameliorating Cyclophosphamide-Induced Intestinal Immune Disorders and Gut Barrier Dysfunctions Based on Microbiome-Metabolomics Analysis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.665901"},{"key":"ref_387","doi-asserted-by":"crossref","unstructured":"Liu, X., Sun, R., Li, Z., Xiao, R., Lv, P., Sun, X., Olson, M.A., and Gong, Y. (2021). Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis. Arch. Biochem. Biophys., 711.","DOI":"10.1016\/j.abb.2021.109019"},{"key":"ref_388","doi-asserted-by":"crossref","unstructured":"Shen, S.H., Zhong, T.Y., Peng, C., Fang, J., and Lv, B. (2020). Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats. BMC Complement. Med. Ther., 20.","DOI":"10.1186\/s12906-020-2835-7"},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","article-title":"MicroRNA","volume":"141","author":"Lu","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"101581","DOI":"10.1016\/j.molmet.2022.101581","article-title":"MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives","volume":"65","author":"Hochreuter","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_391","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-020-0169-z","article-title":"Twist1-induced miR-199a-3p promotes liver fibrosis by suppressing caveolin-2 and activating TGF-\u03b2 pathway","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"100409","DOI":"10.1016\/j.jhepr.2021.100409","article-title":"Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance","volume":"4","author":"Johnson","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"101126","DOI":"10.1016\/j.jhepr.2024.101126","article-title":"Hepatic miR-149-5p upregulation fosters steatosis, inflammation and fibrosis development in mice and in human liver organoids","volume":"6","author":"Delangre","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00018-024-05434-6","article-title":"MicroRNA-411-5p alleviates lipid deposition in metabolic dysfunction-associated steatotic liver disease by targeting the EIF4G2\/FOXO3 axis","volume":"81","author":"Wan","year":"2024","journal-title":"Cell Mol. Life Sci."},{"key":"ref_395","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1440-1746.2009.05949.x","article-title":"Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD","volume":"25","author":"Zheng","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_396","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1080\/21655979.2021.2017698","article-title":"MicroRNA-665-3p exacerbates nonalcoholic fatty liver disease in mice","volume":"13","author":"Yu","year":"2022","journal-title":"Bioengineered"},{"key":"ref_397","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","article-title":"miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease","volume":"25","author":"Long","year":"2019","journal-title":"Mol. Med."},{"key":"ref_398","doi-asserted-by":"crossref","first-page":"155657","DOI":"10.1016\/j.metabol.2023.155657","article-title":"SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis","volume":"146","author":"Shen","year":"2023","journal-title":"Metabolism"},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1194\/jlr.RA120000664","article-title":"The lncRNA Gm15622 stimulates SREBP-1c expression and hepatic lipid accumulation by sponging the miR-742-3p in mice","volume":"61","author":"Ma","year":"2020","journal-title":"J. Lipid Res."},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.actbio.2023.04.002","article-title":"Oligochitosan-based nanovesicles for nonalcoholic fatty liver disease treatment via the FXR\/miR-34a\/SIRT1 regulatory loop","volume":"164","author":"Kong","year":"2023","journal-title":"Acta Biomater."},{"key":"ref_401","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jhep.2023.08.023","article-title":"Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux","volume":"79","author":"Chen","year":"2023","journal-title":"J. Hepatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/9\/4077\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:21:23Z","timestamp":1760030483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/9\/4077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":401,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["ijms26094077"],"URL":"https:\/\/doi.org\/10.3390\/ijms26094077","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]}}}